Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12
Glioblastoma is the most common and aggressive malignant brain tumor and has limited treatment options. Hence, innovative approaches are urgently needed. Oncolytic virus therapy is emerging as a promising modality for cancer treatment due to its tumor-specific targeting and immune-stimulatory proper...
Saved in:
Main Authors: | Lei Wang, Xusha Zhou, Xiaoqing Chen, Yuanyuan Liu, Yue Huang, Yuan Cheng, Peigen Ren, Jing Zhao, Grace Guoying Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-06-01
|
Series: | Molecular Therapy: Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924000419 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of a novel, high-efficacy oncolytic herpes simplex virus type 1 platform equipped with two distinct retargeting modalities
by: Hyun-Yoo Joo, et al.
Published: (2024-03-01) -
4-1BBL-Armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma
by: Wenrui Gao, et al.
Published: (2024-11-01) -
Navigating herpes simplex encephalitis: Family medicine perspectives from Jharkhand, India
by: Amit Kumar Patel, et al.
Published: (2024-12-01) -
Cutaneous perianal herpes simplex virus infection mimicking condylomata acuminata in a renal transplant recipient: A case report and literature review
by: Nabaa Al‐Zubaidi, et al.
Published: (2024-09-01) -
Estimated global and regional economic burden of genital herpes simplex virus infection among 15–49 year-olds in 2016
by: Nathorn Chaiyakunapruk, et al.
Published: (2024-07-01)